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REGULAR ARTICLE
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Key Points

• In 424 patients with
CLL on long-term ibrutinib, AEs were primarily
grade 1/2 and manageable; the majority
of patients continued
therapy.
• AE management requiring dose modification most commonly
occurs in the first year
of ibrutinib and does
not preclude extended
therapy.

Ibrutinib, a ﬁrst-in-class once-daily oral Bruton tyrosine kinase inhibitor indicated for
chronic lymphocytic leukemia (CLL), is continued until progressive disease or unacceptable
toxicity. We conducted an integrated safety analysis of single-agent ibrutinib from
randomized phase 3 studies PCYC-1112 (RESONATE, n 5 195) and PCYC-1115/1116
(RESONATE-2, n 5 135), and examined longer-term safety separately in the phase 1b/2 PCYC1102/1103 study (n 5 94, 420 mg/d). In the integrated analysis (ibrutinib treatment up to
43 months), the most common adverse events (AEs) were primarily grade 1/2; diarrhea
(n 5 173, 52% any-grade; n 5 15, 5% grade 3) and fatigue (n 5 119, 36% any-grade; n 5 10, 3%
grade 3). The most common grade 3/4 AEs were neutropenia (n 5 60, 18%) and pneumonia
(n 5 38, 12%). Over time, prevalence of AEs of interest (diarrhea, fatigue, grade $3 infection,
bleeding, and neutropenia) trended down; prevalence of hypertension increased, but
incidence decreased after year 1. AEs led to dose reductions in 42 (13%) patients and
permanent discontinuations in 37 (11%); dose modiﬁcations due to AEs were most common
during year 1 and decreased in frequency thereafter. The most common AEs (preferred
term) contributing to discontinuation included pneumonia (n 5 4), anemia (n 5 3), and atrial
ﬁbrillation (n 5 3). With long-term follow-up on PCYC-1102/1103 (ibrutinib treatment up to
67 months), grade 3/4 AEs were generally similar to those in the integrated analysis. Overall,
AEs were primarily grade 1/2 and manageable during prolonged ibrutinib treatment in
patients with CLL. These trials were registered at www.clinicaltrials.gov as #NCT01578707,
#NCT01722487, #NCT01724346, #NCT01105247, and #NCT01109069.

Introduction
Ibrutinib, a first-in-class oral once-daily inhibitor of Bruton tyrosine kinase, is approved for the treatment of
patients with chronic lymphocytic leukemia (CLL) and allows for treatment without chemotherapy. The
initial efficacy and tolerability of ibrutinib were shown in a phase 1b/2 study, PCYC-1102/1103, in
patients with previously untreated or relapsed/refractory CLL or small lymphocytic lymphoma (SLL).1,2 In
Submitted 19 November 2018; accepted 1 April 2019. DOI 10.1182/
bloodadvances.2018028761.
Individual participant data from this clinical study are not available; Pharmacyclics LLC,
an AbbVie Company, is currently developing a data-sharing plan.
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this study, single-agent ibrutinib resulted in high response rates and
durable remissions with manageable toxicity, leading to subsequent
randomized phase 3 trials, including PCYC-1112 (RESONATE)3
and PCYC-1115/1116 (RESONATE-2).4 In RESONATE, ibrutinib
significantly prolonged progression-free survival (PFS) and overall
survival (OS) compared with ofatumumab in patients with relapsed/
refractory CLL/SLL. 3 In RESONATE-2, ibrutinib significantly
prolonged PFS and OS compared with chlorambucil in patients
with previously untreated CLL/SLL who were 65 years of age or
older.4
Unlike other treatment options for CLL that are given for finite
numbers of cycles,5-7 ibrutinib is continued until the occurrence of
progressive disease (PD) or unacceptable toxicity, leading to
extended treatment with clinical benefit in most patients.8,9 We
conducted an integrated safety analysis to evaluate the safety and
tolerability of single-agent ibrutinib in a large group of patients
with previously untreated or relapsed/refractory CLL/SLL from
RESONATE and RESONATE-2. We also analyzed separately the
long-term safety of single-agent ibrutinib in patients from PCYC1102/1103.

Methods
Data sources
For the integrated safety analysis, data for all patients treated
with ibrutinib (420 mg daily) in 2 international randomized phase 3 clinical trials and an open-label extension
(RESONATE [NCT01578707] and RESONATE-2 [NCT01722487,
NCT01724346])3,4 were pooled (N 5 330). In RESONATE, 391
patients with CLL/SLL who had received $1 prior therapy
and were inappropriate for treatment or retreatment with purine analogs (supplemental Table 1) were randomly assigned (1:1)
to receive ibrutinib 420 mg once daily until the occurrence of
PD or unacceptable toxicity (n 5 195) or to receive ofatumumab
according to a standard 24-week treatment schedule (n 5 196).3
Following PD, patients in the ofatumumab arm were eligible to
cross over to ibrutinib therapy. In RESONATE-2, 269 previously
untreated patients with CLL/SLL (aged $65 years), without 17p
deletion, requiring treatment were randomly assigned (1:1) to
receive ibrutinib 420 mg once daily until PD or unacceptable
toxicity occurred (n 5 136) or to receive chlorambucil 0.5 mg/kg
(with allowable dose increase to a maximum of 0.8 mg/kg as
tolerated) on days 1 and 15 of a 28-day cycle for 12 cycles
(n 5 133).4 Inclusion of patients aged 65 to 69 years required
a comorbidity precluding chemoimmunotherapy (supplemental
Table 1). All patients dosed in the PCYC-1115 study could enroll
in an extension study (PCYC-1116) at the time of disease
progression or at the time of PCYC-1115 study closure, where
second-line ibrutinib was available for crossover for patients who
progressed on the chlorambucil arm.9
For evaluation of longer-term safety, data were also analyzed
from patients treated in the phase 1b/2 study (PCYC-1102;
NCT01105247).1 Briefly, this study enrolled 132 patients requiring
treatment, of whom 101 had relapsed/refractory CLL/SLL and 31
patients aged $65 years had previously untreated CLL/SLL.
Ninety-four of the 132 patients enrolled, including 67 relapsed/
refractory patients and 27 previously untreated patients, received
ibrutinib 420 mg once daily until PD or unacceptable toxicity
occurred. The remaining 38 patients, including 34 relapsed/
1800
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refractory patients and 4 previously untreated patients, received
ibrutinib 840 mg as initially planned as part of the clinical trial. In this
analysis, only data for all of the patients treated with ibrutinib
420 mg were examined (n 5 94), for a homogenously treated
population. Patients were eligible to continue receiving ibrutinib in
a long-term extension study (PCYC-1103, NCT01109069),10 in
which collection of treatment-emergent adverse events (AEs) was
limited to grade $3 AEs, serious AEs, major hemorrhage, or AEs
leading to ibrutinib dose modification or discontinuation.
Details of the study designs have been published previously.1,2,4,8,10
The studies were approved by the independent ethics committee or
institutional review board at each participating institution and
conducted in accordance with the Declaration of Helsinki and the
International Conference on Harmonization Guidelines for Good
Clinical Practice. All patients provided written informed consent.
Data analyses were performed by Pharmacyclics LLC, and all
authors had full access to study data.

Assessments
Safety was assessed by the frequency and severity of treatmentemergent AEs, including evaluation of AEs that required dose
modifications or treatment discontinuations. Severity of nonhematologic AEs was graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version 4.0,11
with the exception of RESONATE-2, which used version 4.0312). In
addition to examining the most commonly reported AEs, we
assessed select AEs of clinical interest, including diarrhea,
arthralgia, hypertension, rash, bleeding/bruising, fatigue, atrial
fibrillation, and infections. Among these AEs of interest, hypertension, rash, and bleeding/bruising constituted pooled AE terms
that included multiple preferred terms relevant to the AE of interest.
Infections represented pooled AE preferred terms categorized
under the “infections and infestations” system organ class.
Diarrhea, rash, musculoskeletal pain/arthralgia, bruising, and fatigue
are each noted as common adverse reactions to ibrutinib in the
prescribing information; the “warnings and precautions” of the
prescribing information also address infections, bleeding (hemorrhage), and atrial fibrillation.13 Hematologic toxicities were graded
according to the criteria of the International Workshop on Chronic
Lymphocytic Leukemia (2008).14 The protocol-specified criteria for
treatment discontinuations are shown in supplemental Table 2.
Safety data were summarized using descriptive statistics, including
medians for continuous variables and proportions for discrete
variables. Kaplan-Meier methods were used for the landmark
analysis of OS for each patient cohort in the studies evaluated.

Results
Integrated safety analysis
The integrated safety analysis of RESONATE and RESONATE-2
included 330 patients with CLL/SLL (Table 1). The majority of
patients (66%) were male and had an Eastern Cooperative
Oncology Group performance status of 1 (55%). The pooled
cohort included 135 previously untreated patients (41%) and 195
relapsed/refractory patients, as published previously3,4 (35/195
[11%] had been treated with 1 prior regimen, and 160/195 [48%]
had been treated with $2 prior regimens). One patient randomized
to ibrutinib treatment in RESONATE-2 did not receive a dose of
study drug and was excluded from the safety analysis. High-risk
25 JUNE 2019 x VOLUME 3, NUMBER 12

Table 1. Demographics and baseline disease characteristics in
integrated safety analysis

Table 2. Treatment exposure and reasons for discontinuation in
integrated safety analysis

Ibrutinib (N 5 330)

Characteristic
Age, median (range), y

70 (30-89)

Male sex

217 (66)

ECOG performance status

Ibrutinib (N 5 330)
Treatment exposure
Exposure, median (range), mo

29.0 (0.2-42.9)

Duration of treatment, mo

0

139 (42)

#6

32 (10)

1

181 (55)

.6 to 12

18 (5)

2

10 (3)

.12 to 24

34 (10)

169 (51)

.24 to 36

193 (58)

Baseline Rai stage III/IV
Bulky disease $5 cm, n/N (%)

178/329 (54)

.36

53 (16)

Del(11q), n/N (%)

92/319 (29)

Del(17p)*, n/N (%)

60/328 (18)

PD

52 (16)

156/235 (66)

AE

37 (11)

Death

18 (5)

Unmutated IGHV, n/N (%)
Complex karyotype, n/N (%)

45/245 (18)

Treatment discontinuation

124 (38)

b2-microglobulin .3.5 mg/L, n/N (%)

238/309 (77)

Physician decision

9 (3)

Creatinine clearance ,60 mL/min, n/N (%)

121/329 (37)

Withdrawal by patient

8 (2)

CIRS score, median (range)

5 (0-20)

Unless otherwise noted, all data are n (%).

Cytopenia at baseline
Any cytopenia

196 (59)

Absolute neutrophil count #1.5 3 109/L

51 (15)

Platelets #100 3 109/L

109 (33)

Hemoglobin #11 g/dL

140 (42)

No. of prior regimens
0

135 (41)

1

35 (11)

$2

160 (48)

Unless otherwise indicated, data are n (%).
CIRS, Cumulative Illness Rating Scale; ECOG, Eastern Cooperative Oncology Group;
IGHV, immunoglobulin heavy chain variable.
*RESONATE enrolled patients with del(17p); RESONATE-2 excluded patients with
del(17p).

disease features were common (eg, unmutated IGHV, bulky
disease) (Table 1). Patients often were of advanced age: 52%
(173/330) were aged $70 years, and 24% (80/330) had a Cumulative Illness Rating Scale score . 6.
Patients received ibrutinib for a median of 29.0 months (range, 0.242.9) (Table 2). The median relative dose intensity of ibrutinib
was 98% (range, 35-101). Concomitant treatments of interest for
this safety analysis included CYP3 inhibitors (n 5 176, 53%),
antiplatelet agents (n 5 164, 50%), anticoagulants (n 5 92, 28%),
packed red blood cell transfusions (n 5 20, 6%), granulocyte
growth factors (n 5 9, 3%), and IV immunoglobulin (n 5 6, 2%).
Overall, 206 of 330 patients (62%) remained on ibrutinib treatment
at the time of analysis, including 51% (99/195) of relapsed/
refractory patients and 79% (107/135) of previously untreated
patients. The most common primary reasons for discontinuation
were PD (n 5 52, 16%) and AEs (n 5 37, 11%) (Table 2;
supplemental Table 3). Discontinuations due to PD occurred more
frequently among relapsed/refractory patients (25% [48/195]) than
among previously untreated patients (3% [4/135]), whereas
discontinuations due to AEs occurred at a similar rate between
these patient populations (11% [21/195] and 12% [16/135],
25 JUNE 2019 x VOLUME 3, NUMBER 12

respectively). PD with Richter’s transformation occurred in 14
relapsed/refractory patients but only in 1 previously untreated
patient.
All 330 patients in the integrated analysis experienced AEs during
the long-term follow-up. Diarrhea (n 5 173, 52% any-grade; n 5 15,
5% grade 3) and fatigue (n 5 119, 36% any-grade; n 5 10, 3%
grade 3) were the most common all-grade AEs. The most common
grade 3/4 AEs were neutropenia (n 5 22, 7% grade 3; n 5 38,
12% grade 4), pneumonia (n 5 33, 10% grade 3; n 5 5, 2% grade
4), hypertension (n 5 21, 6% grade 3), and anemia (n 5 21, 6%
grade 3; n 5 2, 1% grade 4) (Figure 1).
AEs contributing to dose discontinuations occurred in 10% (33/
330) of patients in year 1, 5% (15/282) of patients in year 1 to 2,
and 6% (15/249) of patients in year 2 to 3 (supplemental Table 4).
AEs contributing to dose discontinuation in .1 patient included
pneumonia (n 5 4, 1%), anemia (n 5 3, 1%), atrial fibrillation (n 5 3,
1%), diarrhea (n 5 2, 1%), subdural hematoma (n 5 2, 1%), and
thrombocytopenia (n 5 2, 1%). Dose reductions due to AEs were
reported in 13% (n 5 42) of patients in the integrated analysis. AEs
leading to dose reduction in .2 of 330 patients were diarrhea
(n 5 5, 2%), neutropenia (n 5 4, 1%), atrial fibrillation (n 5 4, 1%),
anemia (n 5 3, 1%), thrombocytopenia (n 5 3, 1%), and arthralgia
(n 5 3, 1%). Twenty-eight patients (8%) died, most frequently due
to PD (n 5 9, 3%) or pneumonia/lung infection (n 5 7, 2%)
(supplemental Table 5). Seven of the 9 deaths due to PD occurred
in relapsed/refractory patients, including 1 patient who died of
progression with Richter’s transformation. The remaining 2 deaths
due to PD occurred in previously untreated patients.
We further analyzed the frequency and outcomes of select AEs of
clinical interest (Table 3). These select AEs were primarily grade 1/2
and infrequently led to ibrutinib dose adjustments or discontinuations. Grade $3 infections occurred in 31% (101/330) of all
patients and occurred more frequently among relapsed/refractory
patients (36% [70/195]) than among previously untreated patients
SAFETY OF SINGLE-AGENT IBRUTINIB IN CLL/SLL
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Figure 1. Most common treatment-emergent AEs in

Hematologic AEs
Anemia
Neutropenia
Thrombocytopenia
Febrile neutropenia*

20
5

7
18

10

the integrated safety analysis (N 5 330). AEs of any
grade occurring in .15% of patients or grade 3/4 AEs

Grade 1/2 AEs
Grade 3/4 AEs

6

occurring in .3% of patients are shown. *Muscle spasm
and constipation included 1 (,1%) grade 3/4 AE each,

4

and febrile neutropenia included 1 (,1%) grade 1/2

Nonhematologic AEs
Diarrhea
Fatigue
Cough
Nausea
Upper respiratory infection
Pyrexia
Peripheral edema
Arthralgia
Vomiting
Pneumonia
Hypertension
Constipation*
Muscle spasms*
Urinary tract infection
Headache
Dry eye
Sinusitis
Back pain
Atrial fibrillation
Hyponatremia

48

(AEs not shown).

5

33

3
1

32
2

28
28

1

27

1
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1
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2
1

18
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6
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4
2
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6
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1
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2

5

3 3

0

20

40

60
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Patients, %

(23% [31/135]). Opportunistic infections15 of any grade occurred
in 16% (54/330) of all patients, with the most common being
herpes zoster (5% [15/330]) and oral herpes (4% [14/330]).
A higher rate of opportunistic infection was observed among
relapsed/refractory patients compared with those previously untreated (21% [41/196] vs 10% [13/135], respectively). Any-grade
infections leading to dose reductions (1% [3/274] of all infections)
or treatment discontinuations (6% [16/274] of all infections) were
infrequent. The occurrence of any-grade atrial fibrillation was similar
between relapsed/refractory and previously untreated patients
(11% [22/195] and 10% [14/135], respectively). Any-grade
bleeding events were frequent (n 5 182, 55% any-grade combining
multiple AE preferred terms for bleeding); however, grade $3
bleeding events were less common (n 5 17, 5%) and occurred
similarly among relapsed/refractory patients (5% [9/195]) and
previously untreated patients (6% [8/135]). The majority of AEs of
interest resolved during follow-up, per investigator assessment, with
the exception of hypertension (resolution in 36% [25/69] of cases
with standard medical management) (Table 3).
For diarrhea, fatigue, bleeding, rash, and grade $3 infections,
prevalence rates were highest during the first year of treatment and
decreased in frequency thereafter (Table 4). The prevalence of
major hemorrhage events was low and consistent across time
periods (year 1, 2% [8/330]; year 2, 3% [9/280]; year 3, 2%
[5/246]). For arthralgia and atrial fibrillation, rates were relatively
consistent over time. Among patients with atrial fibrillation, a substantial portion of events after the first-year interval were ongoing in
nature; 50% of patients (6/12) with atrial fibrillation during year 2
and 37% of patients (7/19) with atrial fibrillation during year 3 also
had events during earlier years. The incidence of atrial fibrillation
1802
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across time was 6% (20/330) in year 1, 2% (6/280) in year 2, and
5% (12/246) in year 3. Although the prevalence of hypertension
increased over time (year 1, 11% [36/330]; year 2, 15% [41/280];
year 3, 20% [48/246]), the incidence decreased after the first year
(year 1, 11% [36/330]; year 2, 7% [19/280]; year 3, 7% [17/246]).
A similar analysis of hematologic AEs (Table 5) and their prevalence
over time (Table 4) was also conducted. Febrile neutropenia was
reported during the first 2 years of treatment but was uncommon
overall (n 5 14, 4%). Cytopenias occurred more frequently among
relapsed/refractory patients (49% [95/195]) than in previously
untreated patients (36% [49/135]). Cytopenias were reported
most frequently during the first year of ibrutinib (anemia n 5 68,
21%; neutropenia n 5 64, 19%; thrombocytopenia n 5 42, 13%) and
decreased or remained stable during subsequent years of treatment.

Long-term safety analysis
The updated long-term safety analysis of PCYC-1102/1103
included 94 patients who received ibrutinib 420 mg daily for
a median of 47.9 months (range, 0.3-67.4), ;19 months longer
than the median for the integrated analysis. For the entire long-term
cohort, the median relative dose intensity of ibrutinib was 98%
(range, 35-101). Included in this cohort were 25 patients (27%)
who were treated for .5 years with ibrutinib.
Overall, 78 patients (83%) had grade 3/4 AEs, most commonly
hypertension (30% [28/94] grade 3), pneumonia (17% [16/94]
grade 3), neutropenia (9% [8/94] grade 3; 6% [6/94] grade 4), and
atrial fibrillation (11% [10/94] grade 3) (Figure 2). Grade 3/4
infections were reported in 41% (n 5 39) of all patients (36% [34/
94] grade 3; 5% [5/94] grade 4). The most frequently reported
grade 3/4 AEs in PCYC-1102/1103 were generally similar to those
25 JUNE 2019 x VOLUME 3, NUMBER 12

Table 3. Integrated safety analysis: frequency (by severity) of and outcomes with select AEs of clinical interest
Diarrhea

Arthralgia

Fatigue

Atrial fibrillation

HTN*

Infection†

Rash*

Bleeding/bruising*

173 (52)

74 (22)

119 (36)

36 (11)‡

69 (21)

274 (83)

117 (35)

182 (55)§

Grade 1

116 (35)

45 (14)

65 (20)

5 (2)

11 (3)

24 (7)

74 (22)

130 (39)

Grade 2

42 (13)

22 (7)

44 (13)

14 (4)

34 (10)

149 (45)

32 (10)

35 (11)

Grade 3

15 (5)

7 (2)

10 (3)

16 (5)

24 (7)

81 (25)

11 (3)

14 (4)

Grade 4

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

12 (4)

0 (0)

2 (1)

Grade 5

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

8 (2)

0 (0)

1 (,1)

157 (91)

41 (55)

67 (56)

20 (56)

25 (36)

195 (71)

89 (76)

Received concomitant medication for management

64 (37)

45 (61)

3 (3)

30 (83)

45 (65)

257 (94)

65 (56)

41 (23)

Ibrutinib dose held for .7 d||

14 (8)

3 (4)

7 (6)

7 (19)

2 (3)

50 (18)

9 (8)

20 (11)

Ibrutinib dose reduction

5 (3)

3 (4)

2 (2)

4 (11)

0 (0)

3 (1)

3 (3)

4 (2)

Ibrutinib discontinuation#

2 (1)

0 (0)

1 (1)

3 (8)

1 (1)

16 (6)

2 (2)

6 (3)

7

33

57

3

34

13

31

23

Any-grade AE, n (% of all patients)

AE management and resolution, n (% of patients with the AE)
AE(s) resolved{

Median duration until resolution of AE(s),** d

124 (68)

HTN, hypertension.
*Pooled AE terms include multiple preferred terms relevant to the AE of interest.
†System organ class.
‡AE severity grade was not reported for 1 patient with atrial fibrillation.
§Twenty-one patients reported 25 major hemorrhage events, including grade 1 subdural hematoma (n 5 1); grade 2 hyphema, subdural hematoma, and vitreous hemorrhage (n 5 1 each);
grade 3 hematuria (n 5 3), postprocedural hemorrhage (n 5 2), spontaneous hematoma (n 5 2), subdural hematoma (n 5 2), traumatic hematoma (n 5 2), and ecchymosis, epistaxis,
gastrointestinal hemorrhage, rectal hemorrhage, subarachnoid hematoma, subarachnoid hemorrhage, and vitreous hemorrhage (n 5 1 each); grade 4 cerebral hemorrhage and subdural
hematoma (n 5 1 each); and grade 5 subdural hematoma (n 5 1).
{Resolved or resolved with sequelae, as assessed by the investigator. If patient had multiple AEs, then all AEs must have been deemed by the investigator to be resolved to be counted as
resolved.
||The onset of the missing dose event must have occurred on or #7 d after the related AE onset date.
#Includes patients with any AEs contributing to treatment discontinuation.
**Median event duration based on all resolved AEs.

found in the integrated safety analysis. In this study, 8 patients
developed Richter’s transformation.
Second malignancies of any grade were identified in 15 patients,
most commonly basal cell carcinoma (n 5 4), squamous cell

carcinoma of the skin (n 5 4), and myelodysplastic syndrome (n 5
2). In 7 of these 15 patients, the second malignancy was diagnosed
during the first year of ibrutinib therapy. The other cases occurred
over time through the latest follow-up conducted after .5 years of
treatment.

Table 4. Prevalence of select AEs of clinical interest over time with ibrutinib treatment in the integrated safety analysis (N 5 330)
0-1 y (N 5 330)

>1 to 2 y (n 5 280)

>2 to 3 y (n 5 246)

Anemia

68 (21)

24 (9)

21 (9)

Neutropenia

64 (19)

26 (9)

15 (6)

Thrombocytopenia

42 (13)

26 (9)

25 (10)

Febrile neutropenia

8 (2)

6 (2)

0

Diarrhea

155 (47)

56 (20)

38 (15)

Fatigue

97 (29)

65 (23)

53 (22)

Arthralgia

53 (16)

35 (13)

33 (13)

Atrial fibrillation

20 (6)

12 (4)

19 (8)

AE, n (%)
Hematologic AEs

Nonhematologic AEs

Pooled AE terms* or system organ class
Hypertension

36 (11)

41 (15)

48 (20)

147 (45)

100 (36)

68 (28)

Rash

88 (27)

58 (21)

38 (15)

Grade $3 infections†

77 (23)

38 (14)

24 (10)

Bleeding

*Pooled AE terms include multiple preferred terms relevant to the AE of interest.
†AEs reported under “infections and infestations” system organ class category.
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Table 5. Integrated safety analysis: frequency (by severity) of and outcomes with hematologic AEs
Neutropenia

Anemia

Thrombocytopenia

Febrile neutropenia

78 (24)

88 (27)

53 (16)

14 (4)

Grade 1

6 (2)

24 (7)

18 (5)

0 (0)

Grade 2

12 (4)

41 (12)

15 (5)

Grade 3

22 (7)

21 (6)

12 (4)

13 (4)

Grade 4

38 (12)

2 (1)

8 (2)

0 (0)

Grade 5

0 (0)

0 (0)

0 (0)

0 (0)

66 (85)

64 (73)

26 (49)

14 (100)

Received concomitant medication for management

16 (21)

28 (32)

2 (4)

7 (50)

Ibrutinib dose held for .7 d†

18 (23)

9 (10)

7 (13)

3 (21)

Any-grade AE, n (% of all patients)

1 (, 1)

AE management and resolution, n (% of patients with the AE)
AE(s) resolved*

Ibrutinib dose reduction

4 (5)

3 (3)

3 (6)

0 (0)

Ibrutinib discontinuation‡

1 (1)

3 (3)

3 (6)

0 (0)

14

17

15

5

Median duration until resolution of AE(s),§ d

*Resolved or resolved with sequelae, as assessed by the investigator. If patient had multiple AEs, then all AEs must have been deemed by the investigator to be resolved to be counted as
resolved.
†The onset of the missing dose event must have occurred on or #7 d after the related AE onset date.
‡Includes patients with any AEs contributing to treatment discontinuation.
§Median event duration based on all resolved AEs.

Survival
Landmark survival rates were estimated separately for previously
untreated and relapsed/refractory patients across the 3 clinical
studies evaluated (supplemental Table 6). For previously untreated

patients, the OS rate was 95% at 2 years in RESONATE-2 and
91% at 5 years in PCYC-1102/1103. For patients with relapsed/
refractory disease, the OS rate was 74% at 3 years in RESONATE
and 62% at 5 years in PCYC-1102/1103.

Discussion
This article characterizes the long-term safety of single-agent
ibrutinib for the treatment of previously untreated and relapsed/
refractory CLL/SLL. It includes safety information for the largest
number of ibrutinib-treated patients with CLL/SLL described to
date, who have received continuous treatment with ibrutinib for the
longest period of time (in some cases .5 years).

Hematologic AEs
Neutropenia
Thrombocytopenia
Lymphocyte count decreased
Lymphocyte count increased
Leukocytosis
Neutrophil count decreased

15
7
6
4
3
3
Nonhematologic AEs
30

Hypertension
Pneumonia
Atrial fibrillation
Diarrhea
Cellulitis
Hyperglycemia
Fatigue
Sepsis
Acute kidney injury
Dehydration
Hypokalemia
Syncope
Decreased appetite
Hyponatremia
Hypoxia
Hypotension
Chronic lymphocytic leukemia
Sinusitis
Urinary tract infection
Nausea
Vomiting
Asthenia
Pyrexia
Back pain
Weight decreased

17
11
9
7
7
6
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
0

20

40

60

80

100

Patients, %
Figure 2. Most common grade 3/4 AEs in the PCYC-1102/1103 long-term
cohort (n 5 94). Grade 3/4 AEs occurring in .3% of patients are shown.
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Toxicities observed with prolonged continuous dosing of ibrutinib
remain unchanged when compared with earlier reports with shorter
treatment durations.1-4,8 No new treatment-emergent events have
been observed, and the prevalence rates of previously described events fall within the same range, with the exception of
hypertension, for which prevalence increased over time. Additional
analysis of the integrated safety data over time found that rates of
many early-onset toxicities, including rash, fatigue, and diarrhea,
declined over time, despite ongoing drug dosing, and few resulted
in treatment discontinuations. In contrast, atrial fibrillation rates were
persistent over time. Previous analyses have shown that atrial
fibrillation typically occurs early after ibrutinib initiation and remains
constant or declines over time.8,16 Patients treated with ibrutinib
should be periodically monitored clinically for atrial fibrillation.17 For
hypertension, although the incidence decreased over time, the
increase in prevalence across the study underscores the need for
vigilant monitoring and management. Bleeding events, which were
primarily low-grade (grade 1/2) events, were most common during
the first year (45%) and decreased in prevalence over time,
although these events remained relatively frequent at 28% during
the third year of ibrutinib treatment. Importantly, major hemorrhage
25 JUNE 2019 x VOLUME 3, NUMBER 12

events were less common over the course of treatment. Effective
monitoring and management of these complications likely led to
infrequent dose reductions or discontinuation due to these AEs.
Furthermore, ibrutinib was associated with relatively low rates of
hematologic toxicities with continued dosing; cases of febrile
neutropenia were particularly uncommon.
The significant ongoing disease control observed with continuous
ibrutinib treatment likely contributes to its overall favorable safety
profile. For example, heavily pretreated relapsed/refractory CLL/
SLL patients often experience treatment-related cytopenias,6,18 and
the incidence of infection and mortality due to infection rises
dramatically in these patients.19-21 Infection is common in patients
with CLL owing to the underlying disease, especially in patients
whose disease is at an advanced stage and in patients who are
exposed to immunosuppressive therapies. 10,22,23 This study
demonstrates progressive declines in infection and neutropenia
rates over time during ibrutinib treatment, consistent with previous
analyses.10,16,24 Following the approval of ibrutinib in CLL, there
have been specific reports of opportunistic infections in patients
treated with ibrutinib.23,25 In the current report, the rate of
opportunistic infections observed with ibrutinib was higher among
patients who had received $1 prior therapy compared with
previously untreated patients. Patients should be monitored for
infection during ibrutinib therapy, with standard-of-care prophylaxis
for opportunistic infections in patients at risk and anti-infective
therapy administered as indicated.
This safety analysis, together with a median ibrutinib dose intensity
of 98%, demonstrates that continuous treatment with ibrutinib is
possible without significant AEs limiting its ongoing use in most
patients. This finding is noteworthy in the context of previous reports
that have shown that the quality and depth of the clinical response
increase over time with continued ibrutinib treatment.10,26-28 A
recent network meta-analysis of randomized clinical trials showed
superior benefit in survival and safety with ibrutinib compared with
other first-line treatments for CLL.29 According to the network metaanalysis of safety outcomes, ibrutinib was associated with the
lowest risk of treatment discontinuations and discontinuations due
to AEs vs comparators in the overall first-line population and the
fludarabine-ineligible population.29 Of note, higher discontinuation
due to toxicity has been reported with ibrutinib outside of the clinical
study setting.30 Such variations in discontinuation rates between
“real-world” and clinical studies are likely due to differences in
patient and study characteristics. Long-term disease control with
a well-tolerated therapy is an important goal of CLL/SLL treatment.
It is especially important given that the average CLL/SLL patient is
.70 years old when treatment is first required, and many of these
patients will have comorbidities limiting the use of traditional
chemoimmunotherapy.31 Further follow-up of patients treated in
clinical trials with ibrutinib will provide additional data to clinicians
regarding the tolerability and safety of long-term treatment with
ibrutinib in relapsed/refractory and first-line settings.
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